# Crohn Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/crohn-disease

> 8 upcoming FDA catalysts in Crohn Disease: LY4395089 (LLY) on June 2027 (primary completion); LY4395089 (LLY) on Jun to Sep 2027 (topline data readout); Tremfya (guselkumab, JNJ) on Jun to Sep 2028 (topline data readout); Tremfya (guselkumab, JNJ) on June 2028 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 2027 | [LY4395089 primary completion](https://sec-api.dev/pdufa/ly4395089) | LLY | Crohn Disease | scheduled | "NCT07483099 (A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07483099)) |
| Jun to Sep 2027 | [LY4395089 topline data readout](https://sec-api.dev/pdufa/ly4395089) | LLY | Crohn Disease | scheduled | "NCT07483099 (A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07483099)) |
| Jun to Sep 2028 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn Disease | scheduled | "NCT07577843 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07577843)) |
| June 2028 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn Disease | scheduled | "NCT07577843 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07577843)) |
| Sep to Dec 2028 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Crohn Disease | scheduled | "NCT07196722 (A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196722)) |
| September 2028 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Crohn Disease | scheduled | "NCT07196722 (A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196722)) |
| Nov 2028 to Feb 2029 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn Disease | scheduled | "NCT07499232 (A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07499232)) |
| November 2028 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn Disease | scheduled | "NCT07499232 (A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07499232)) |

## Drugs

- [LY4395089](https://sec-api.dev/pdufa/ly4395089) (LLY)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/crohn-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Crohn Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/crohn-disease

```bibtex
@misc{secapidev_indications_crohn_disease_20261116,
  title        = {Crohn Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/crohn-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_crohn_disease_20261116","title":"Crohn Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/crohn-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
